B cell non-Hodgkin lymphoma
Conditions
Interventions
Group1:1mg dosage
Group2:2mg dosage
Group3:4mg dosage
Sponsors
Xinqiao Hospital Affiliated to Army Military Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with B-cell non-Hodgkin's lymphoma diagnosed by histopathology of age >=18 years; 2. Achieve the curative effect of PR and above after front-line treatment; 3. ECOG-PS 0-2; 4. Bone marrow hematopoietic function is basically normal blood routine: white blood cell count> 3000/uL, absolute neutrophil count >=1.5 x 10^9/L (granulocyte colony stimulating factor is allowed), platelet count >= 75x10^9/L (allowing blood transfusion to reach The minimum platelet count), hemoglobin >=9.0g/dL (pre-infusion of red blood cells or the use of recombinant human erythropoietin is allowed). If lymphoma invades the bone marrow or spleen and causes abnormal peripheral blood indicators, the investigator can judge whether it is suitablefor inclusion; 5. The main organ function is normal: liver function: serum bilirubin= 6 months; 7. The patient was fully informed and signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients who are known to have a history of severe allergies to pomalidomide or immunomodulatory drugs or those who have any contraindications; 2. Heart diseases with clinical significance include acute myocardial infarction, congestive heart failure (NYHA) grade III or IV in the 6 months before screening for unstable angina pectoris; 3. Subjects with acquired and congenital immunodeficiency diseases, including but not limited to HIV-infected persons; 4. Women during pregnancy or lactation; 5. Systemic treatment of active bacterial, fungal and/or viral infections that cannot be controlled; 6. Have a history of serious neurological or psychiatric diseases, including dementia or epilepsy; 7. Concomitant with other malignant tumors within the last 5 years or at the same time, excluding cured skin basal cell carcinoma or cervical carcinoma in situ, or early prostate cancer that does not require systemic treatment, or only requires surgery to treat early breast cancer; 8. Drug abuse, medical, psychological or social conditions that may interfere with the subject's participation in research or evaluation of research results; 9. Patients considered by the investigator to be unsuitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of relief;Overall survival;Safety; | — |
Countries
China
Contacts
Public ContactXiang Qianqian, Gao Li
Xinqiao Hospital Affiliated to Army Military Medical University
Outcome results
None listed